Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan, 430022, China.
Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
Anticancer Agents Med Chem. 2023;23(4):461-469. doi: 10.2174/1871520622666220601115458.
To investigate the safety and efficacy of lobaplatin-TACE in treating primary hepatocellular carcinoma.
The data of 536 patients who underwent TACE in the interventional department from January 2016 to January 2020 were collected. Patients were divided into two groups according to the chemotherapeutic drugs used in TACE.: the epirubicin-TACE group (N = 260) and the lobaplatin-TACE group (N = 276). Primary study endpoint: (1) The tumor response after TACE; (2) The survival rates; Secondary study endpoints:(1) Changes in liver function and blood routine before and after TACE; (2) Occurrence of the post-embolization syndrome and infection after TACE.
The ORR was 35.0% in the epirubicin-TACE group and 51.1% in the lobaplatin-TACE group (p=0.001). The DCR was 73.1% in the epirubicin-TACE group and 82.2% in the lobaplatin-TACE group (p=0.011). The 6-month, 9- month, 12-month, and 15-month survival rates were higher in the lobaplatin-TACE group than in the epirubicin-TACE group (p=0.029, p=0.001, p=0.005, p=0.002). mOS: Epirubicin-TACE group,14.8 months; Lobaplatin-TACE group,18.6 months (p=0.007). mPFS: Epirubicin-TACE group,9.5 months; Lobaplatin-TACE group,12.8 months (P =0.000). There was no statistical difference in ALT, AST, total bilirubin and Leucocyte after TACE between the two groups (p=0.343, p=0.368, p=0.288, p=0.359). The platelet decrease after TACE was more significant in the lobaplatin- TACE group than in the epirubicin-TACE group (p=0.046). There was no statistical difference in the incidence rate of abdominal pain, fever and infection after TACE between the two groups (p=0.502, p=0.602, p=0.726). The incidence of vomiting after TACE in the lobaplatin-TACE group was higher than that in the epirubicin-TACE group (p=0.003).
Lobaplatin-TACE has a higher tumor response rate and survival rate. Lobaplatin-TACE is a safe and effective treatment strategy; it is worthy of clinical application.
探讨洛铂联合 TACE 治疗原发性肝癌的安全性和有效性。
收集 2016 年 1 月至 2020 年 1 月期间介入科行 TACE 治疗的 536 例患者的临床资料。根据 TACE 中使用的化疗药物将患者分为两组：表柔比星 TACE 组（n = 260）和洛铂 TACE 组（n = 276）。主要研究终点：（1）TACE 后的肿瘤反应；（2）生存率；次要研究终点：（1）TACE 前后肝功能和血常规的变化；（2）TACE 后栓塞后综合征和感染的发生。
表柔比星 TACE 组的客观缓解率（ORR）为 35.0%，洛铂 TACE 组为 51.1%（p=0.001）。表柔比星 TACE 组疾病控制率（DCR）为 73.1%，洛铂 TACE 组为 82.2%（p=0.011）。洛铂 TACE 组的 6 个月、9 个月、12 个月和 15 个月生存率均高于表柔比星 TACE 组（p=0.029、p=0.001、p=0.005、p=0.002）。mOS：表柔比星 TACE 组 14.8 个月；洛铂 TACE 组 18.6 个月（p=0.007）。mPFS：表柔比星 TACE 组 9.5 个月；洛铂 TACE 组 12.8 个月（P =0.000）。两组 TACE 后 ALT、AST、总胆红素和白细胞均无统计学差异（p=0.343、p=0.368、p=0.288、p=0.359）。TACE 后血小板减少在洛铂-TACE 组更为显著，与表柔比星-TACE 组相比差异有统计学意义（p=0.046）。两组 TACE 后腹痛、发热和感染的发生率无统计学差异（p=0.502、p=0.602、p=0.726）。TACE 后洛铂-TACE 组呕吐的发生率高于表柔比星-TACE 组（p=0.003）。
洛铂联合 TACE 治疗原发性肝癌的肿瘤反应率和生存率更高。洛铂联合 TACE 是一种安全有效的治疗策略；值得临床应用。
